Gotowa bibliografia na temat „Hexahydropyrimidines”
Utwórz poprawne odniesienie w stylach APA, MLA, Chicago, Harvard i wielu innych
Spis treści
Zobacz listy aktualnych artykułów, książek, rozpraw, streszczeń i innych źródeł naukowych na temat „Hexahydropyrimidines”.
Przycisk „Dodaj do bibliografii” jest dostępny obok każdej pracy w bibliografii. Użyj go – a my automatycznie utworzymy odniesienie bibliograficzne do wybranej pracy w stylu cytowania, którego potrzebujesz: APA, MLA, Harvard, Chicago, Vancouver itp.
Możesz również pobrać pełny tekst publikacji naukowej w formacie „.pdf” i przeczytać adnotację do pracy online, jeśli odpowiednie parametry są dostępne w metadanych.
Artykuły w czasopismach na temat "Hexahydropyrimidines"
Moser, Shasta, Ryan Church, M. Brad Peori i Keith Vaughan. "Triazene derivatives of (1,x)-diazacycloalkanes. Part IV.1 Synthesis and characterization of 1-[2-aryl-1-diazenyl]-3-(3-[2-aryl-1-diazenyl]hexahydro-1-pyrimidinylmethyl)hexahydropyrimidines and 1-(5,5-dimethyl-3-[2-aryl-1-diazenyl]hexahydro-1-pyrimidinylmethyl)-5,5-dimethyl-3-[2-aryl-1-diazenyl]hexahydropyrimidines from the reaction of diazonium salts with mixtures of formaldehyde and 1,3-diaminopropanes". Canadian Journal of Chemistry 83, nr 8 (1.08.2005): 1071–83. http://dx.doi.org/10.1139/v05-131.
Pełny tekst źródłaBadamshin, A. G., D. R. Latypova i V. A. Dokichev. "Synthesis of Polyfunctionalized Hexahydropyrimidines". Russian Journal of Organic Chemistry 55, nr 2 (luty 2019): 168–73. http://dx.doi.org/10.1134/s1070428019020076.
Pełny tekst źródłaZelenin, Kirill N., Valeriy V. Alekseyev, Ilya V. Ukraintsev i Igor V. Tselinsky. "2-SUBSTITUTED HEXAHYDROPYRIMIDINES AND THEIR TAUTOMERISM". Organic Preparations and Procedures International 30, nr 1 (luty 1998): 53–61. http://dx.doi.org/10.1080/00304949809355259.
Pełny tekst źródłaKatritzky, Alan R., Sandeep K. Singh i Hai-Ying He. "Novel Syntheses of Hexahydropyrimidines and Tetrahydroquinazolines". Journal of Organic Chemistry 67, nr 9 (maj 2002): 3115–17. http://dx.doi.org/10.1021/jo010927x.
Pełny tekst źródłaLuk'yanov, O. A., G. V. Pokhvisneva i T. V. Ternikova. "N,N?-Diacylated imidazolidines and hexahydropyrimidines". Russian Chemical Bulletin 43, nr 8 (sierpień 1994): 1376–80. http://dx.doi.org/10.1007/bf00703698.
Pełny tekst źródłaFarrell, Joshua R., Jonathan Niconchuk, Christine S. Higham i Brittany W. Bergeron. "Phenol derivatized hexahydropyrimidines prepared from Mannich condensations". Tetrahedron Letters 48, nr 45 (listopad 2007): 8034–36. http://dx.doi.org/10.1016/j.tetlet.2007.09.038.
Pełny tekst źródłaShafikova, E. A., D. V. Petrov, T. A. Sapozhnikova, N. J. Baschenko i V. A. Dokichev. "Synthesis of norbornane series tetra- and hexahydropyrimidines". Chemistry of Heterocyclic Compounds 45, nr 6 (czerwiec 2009): 685–90. http://dx.doi.org/10.1007/s10593-009-0328-1.
Pełny tekst źródłaTingley, Reid, M. Brad Peori, Ryan Church i Keith Vaughan. "Triazene derivatives of (1,x)-diazacycloalkanes. Part V.1 Synthesis and characterization of 4-ethyl-3-({6-ethyl-3-[2-aryl-1-diazenyl]hexahydro-1-pyrimidinyl}methyl)-1-[2-aryl-1-diazenyl)hexa- hydropyrimidines from the reaction of diazonium salts with mixtures of formaldehyde and 1,3-diaminopentane". Canadian Journal of Chemistry 83, nr 10 (1.10.2005): 1799–807. http://dx.doi.org/10.1139/v05-192.
Pełny tekst źródłaBergeron, Raymond J., i Howard W. Seligsohn. "Hexahydropyrimidines as masked spermidine vectors in drug delivery". Bioorganic Chemistry 14, nr 4 (grudzień 1986): 345–55. http://dx.doi.org/10.1016/0045-2068(86)90001-5.
Pełny tekst źródłaLUK'YANOV, O. A., G. V. POKHVISNEVA i T. V. TERNIKOVA. "ChemInform Abstract: N,N′-Diacylated Imidazolidines and Hexahydropyrimidines." ChemInform 26, nr 12 (18.08.2010): no. http://dx.doi.org/10.1002/chin.199512067.
Pełny tekst źródłaRozprawy doktorskie na temat "Hexahydropyrimidines"
Locke, Julie Myree, University of Western Sydney, College of Health and Science i School of Biomedical and Health Sciences. "Synthetic and conformational studies of hexahydropyrimidines and related heterocycles". THESIS_CHS_BHS_Locke_J.xml, 2003. http://handle.uws.edu.au:8081/1959.7/638.
Pełny tekst źródłaDoctor of Philosophy (PhD)
Locke, Julie Myree. "Synthetic and conformational studies of hexahydropyrimidines and related heterocycles". Thesis, View thesis, 2003. http://handle.uws.edu.au:8081/1959.7/638.
Pełny tekst źródłaLocke, Julie Myree. "Synthetic and conformational studies of hexahydropyrimidines and related heterocycles /". View thesis, 2003. http://library.uws.edu.au/adt-NUWS/public/adt-NUWS20060517.103404/index.html.
Pełny tekst źródła"A thesis submitted in partial fulfilment of the requirements of the degree of Doctor of Philosophy , University of Western Sydney, Campbelltown, February 2003". Includes references : leaves 188 - 200, and appendices.
Paula, Daniela Trivelato da Silveira de. "Atividade de análogos de imidazolidinas e hexahidropirimidinas em espécies de Leishmania associadas à leishmaniose cutânea". Universidade Federal de Juiz de Fora, 2012. https://repositorio.ufjf.br/jspui/handle/ufjf/2016.
Pełny tekst źródłaApproved for entry into archive by Adriana Oliveira (adriana.oliveira@ufjf.edu.br) on 2016-07-13T16:33:54Z (GMT) No. of bitstreams: 1 danielatrivelatodasilveiradepaula.pdf: 1200045 bytes, checksum: f8ebaf5127aea71d80cdf654a3635613 (MD5)
Made available in DSpace on 2016-07-13T16:33:55Z (GMT). No. of bitstreams: 1 danielatrivelatodasilveiradepaula.pdf: 1200045 bytes, checksum: f8ebaf5127aea71d80cdf654a3635613 (MD5) Previous issue date: 2012-02-15
CAPES - Coordenação de Aperfeiçoamento de Pessoal de Nível Superior
As leishmanioses são doenças causadas por protozoários do gênero Leishmania e apresentam um amplo espectro de manifestações clínicas. São consideradas doenças tropicais negligenciadas e encontram-se presentes atualmente em 98 países, afetando 12 milhões de pessoas, com 2 milhões de novos casos por ano. O tratamento baseia-se principalmente na administração de antimoniais pentavalentes, que apresentam diversos problemas, incluindo alta toxicidade, efeitos adversos e o aparecimento de cepas resistentes. Diante deste fato é indiscutível a necessidade de novas drogas para a quimioterapia destas doenças. Neste sentido, o objetivo do trabalho consistiu na avaliação da atividade de compostos análogos de imidazolidinas e hexahidropirimidinas em diferentes espécies de Leishmania relacionadas à manifestações cutâneas. Foram testados 18 compostos, sendo nove análogos de imidazolidinas e nove de hexahidropirimidinas. Inicialmente os testes foram realizados em formas promastigotas de L. amazonensis, L. braziliensis e L. major e em macrófagos peritoneais de camundongos. A viabilidade destas células foi mensurada pelo método colorimétrico do MTT. Posteriormente, compostos com baixa toxicidade para macrófagos e efetiva atividade antipromastigota foram selecionados para os testes em amastigotas, cuja metodologia foi baseada na coloração por giemsa e contagem dos parasitos intracelulares. Nenhum dos compostos testados apresentou atividade citotóxica significativa para macrófagos. Dentre os análogos de imidazolidinas, cinco apresentaram atividade efetiva em formas promastigotas de Leishmania, com CI50 variando de 6,18 a 34,93 μM. Os compostos 2 e 3 foram os que apresentaram maior atividade antipromastigota e antiamastigota em Leishmania, sendo o composto 2, que possui uma diamina, o mais ativo. Para os análogos de hexahidropirimidinas, promastigotas de L. major foram os únicos sensíveis com CI50 variando de 13,63 a 33,50 μM. Somente o composto 14 se mostrou ativo em formas intracelulares do parasito. Verificou-se nos compostos testados uma relação estrutura-atividade, bem como diferenças de sensibilidades entre as espécies de Leishmania e entre as formas promastigotas e amastigotas. Os análogos de imidazolidinas apresentaram CI50 das formas promastigotas e amastigotas próximos, sugerindo que o mecanismo de ação não depende da imunomodulação da célula hospedeira. Em relação às hexahidropirimidinas, o composto 14 não aumentou os níveis da produção do NO, indicando que o mecanismo de ação não ocorre via modulação de NO. De modo geral, o estudo mostrou que os compostos analisados possuem significativo potencial leishmanicida, embora mais pesquisas sejam necessárias, no sentido de se identificar o mecanismo de ação dos mesmos.
Leishmaniasis is a disease caused by protozoa of the genus Leishmania, presenting a broad spectrum of clinical manifestations. Nowadays it is present in 98 countries, affecting 12 million people, with 2 million new cases per year. The current treatment is based mainly on administration of pentavalent antimonials which have several problems, including high toxicity, adverse effects and the emergence of resistants strains. Given this fact, there is a clear need for development of new drugs for chemotherapy of these diseases. In this sense, the aims of this study were to assess the activity of imidazolidine and hexahydropyrimidine analogues compounds in different species of Leishmania which are related to cutaneous manifestations. Eighteen compounds were tested, nine imidazolidine analogues and nine hexahydropyrimidine analogues. Initially the tests were performed on promastigote forms of L. amazonensis, L. braziliensis and L. major and murine peritoneal macrophages. The viability of these cells was measured by the MTT colorimetric method. Subsequently, compounds with low toxicity for macrophages and effective antipromastigote activity were selected for the tests in amastigote forms, which methodology was based on Giemsa staining and counting of intracellular parasites. None of compounds showed significant cytotoxic activity for macrophages. Among the imidazolidine analogues, five showed effective activity in promastigotes of Leishmania, with IC50 ranging from 6.18 to 34.93 μM. The compounds 2 and 3 presented the highest activity for antipromastigote and antiamastigote assays, and the compound 2, with a diamine, was the most active. For hexahydropyrimidine analogues, only promastigotes of L. major were sensitive of the compounds, with IC50 ranging from 13.63 to 33.50 μM. Only the compound 14 showed activity on intracellular forms of the parasite. It was observed in the compounds tested a structure-activity relationship as well as differences in sensitivity between Leishmania species and promastigotes and amastigotes forms. The imidazolidine analogues showed a close IC50 for promastigote and amastigote forms, suggesting that their action mechanism action does not depend on immunomodulation of the host cell. Regarding hexahydropyrimidine analogues, the compound 14 did not increasead NO production, indicating that the action mechanism was unlikely to be due to NO modulation. In general, this study showed that the compounds studied have potential leishmanicidal activity, although more research are necessary, in order to identify the mechanism of action of these compounds.
Części książek na temat "Hexahydropyrimidines"
RAMEY, C. E., i C. J. ROSTEK. "Hexahydropyrimidines as Hindered Amine Light Stabilizers". W ACS Symposium Series, 149–55. Washington, D.C.: American Chemical Society, 1985. http://dx.doi.org/10.1021/bk-1985-0280.ch012.
Pełny tekst źródła"Hexahydropyrimidin-5-ide, Hexahydropyrimidine 5-Anion to 1,4-Dihydropyrimidin-1-ium". W Substance index, redaktorzy Backes, Fröhlich i Padeken. Stuttgart: Georg Thieme Verlag, 1999. http://dx.doi.org/10.1055/b-0035-114303.
Pełny tekst źródła